AR071774A1 - Sal de acetato de un compuesto peptidico que tiene actividad antitumoral y su uso. - Google Patents
Sal de acetato de un compuesto peptidico que tiene actividad antitumoral y su uso.Info
- Publication number
- AR071774A1 AR071774A1 ARP090101720A ARP090101720A AR071774A1 AR 071774 A1 AR071774 A1 AR 071774A1 AR P090101720 A ARP090101720 A AR P090101720A AR P090101720 A ARP090101720 A AR P090101720A AR 071774 A1 AR071774 A1 AR 071774A1
- Authority
- AR
- Argentina
- Prior art keywords
- arg
- acetate salt
- peptidic compound
- cbp501
- prodrugs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Adem s provee un metodo para la profilaxis o el tratamiento del c ncer en un mam¡fero, que comprende administrar una cantidad terapeuticamente efectiva de CBP501, una de sus prodrogas o una de sus sales farmaceuticamente aceptables al mam¡fero, en donde CBP501, una de sus prodrogas o una de sus sales farmaceuticamente aceptables es administrada simult neamente con, o antes de, la administracion de un agente que dana el cido nucleico. Reivindicacion 1: Una sal acetato de un compuesto pept¡dico caracterizado por la secuencia: (d-Bpa) (d-Ser) (d-Trp) (d- Ser) (d-Phe-2,3,4,5, 6-F) (d-Cha) (d-Arg) (d-Arg) (d-Arg) (d-Gln) (d-Arg) (d-Arg) (SEQ ID Nø:1). Reivindicacion 2: Un agente para la profilaxis o el tratamiento de un trastorno proliferativo celular, caracterizado porque comprende la sal acetato del compuesto pept¡dico de acuerdo con la reivindicacion 1 como un ingrediente activo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5319008P | 2008-05-14 | 2008-05-14 | |
| US11684908P | 2008-11-21 | 2008-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071774A1 true AR071774A1 (es) | 2010-07-14 |
Family
ID=40886711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101720A AR071774A1 (es) | 2008-05-14 | 2009-05-13 | Sal de acetato de un compuesto peptidico que tiene actividad antitumoral y su uso. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20100112089A1 (es) |
| CN (1) | CN102149725A (es) |
| AR (1) | AR071774A1 (es) |
| CL (1) | CL2009001156A1 (es) |
| PE (1) | PE20091924A1 (es) |
| RU (1) | RU2010150964A (es) |
| TW (1) | TW201000116A (es) |
| UY (1) | UY31826A (es) |
| WO (1) | WO2009139497A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2829877B1 (en) * | 2012-03-18 | 2020-01-22 | Shiseido Company, Ltd. | Apparatus, system and method for analyzing disease sample |
| RS60180B1 (sr) * | 2013-06-24 | 2020-06-30 | Canbas Co Ltd | Kombinovana upotreba peptida i peptidomimetika i tretman subpopulacija pacijenata obolelih od kancera |
| GB201401877D0 (en) | 2014-02-04 | 2014-03-19 | Univ Tromsoe | Peptides |
| TWI805542B (zh) * | 2015-10-23 | 2023-06-21 | 日商坎巴斯有限公司 | 用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合 |
| US10149887B2 (en) * | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| EP3377068B1 (en) | 2015-11-20 | 2025-03-26 | Senhwa Biosciences, Inc. | Combination therapy of tetracyclic quinolone analogs for treating cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1218494E (pt) * | 1999-09-22 | 2005-08-31 | Canbas Co Ltd | Composicoes e metodos para inibir a paragem do ciclo celular g2 e para sensibilizar celulas perante agentes que danificam o adn |
| KR101103412B1 (ko) * | 2002-01-17 | 2012-01-06 | 다케다 파머수티컬 컴패니 리미티드 | 항증식 활성을 지니고／지니거나 핵산 손상제 또는처리제를 증강시키는 펩티드 및 펩티드모방체 |
| US7125842B2 (en) * | 2003-04-07 | 2006-10-24 | Canbas Co. Ltd. | Anti-fungal compounds and methods of use |
| WO2005014856A1 (en) * | 2003-08-08 | 2005-02-17 | Canbas Co., Ltd. | Sensitivity test to predict efficacy of anti-cancer therapies |
| AU2006201635A1 (en) * | 2005-10-20 | 2007-05-10 | Ludwig Institute For Cancer Research | Novel inhibitors and methods for their preparation |
| US20100135903A1 (en) * | 2006-10-11 | 2010-06-03 | Medvet Science Pty. Ltd. | Use of a dna damaging agent and a ligand for the treatment of cancer |
-
2009
- 2009-05-13 UY UY0001031826A patent/UY31826A/es not_active Application Discontinuation
- 2009-05-13 PE PE2009000669A patent/PE20091924A1/es not_active Application Discontinuation
- 2009-05-13 CL CL2009001156A patent/CL2009001156A1/es unknown
- 2009-05-13 TW TW098115779A patent/TW201000116A/zh unknown
- 2009-05-13 WO PCT/JP2009/059238 patent/WO2009139497A1/en not_active Ceased
- 2009-05-13 AR ARP090101720A patent/AR071774A1/es not_active Application Discontinuation
- 2009-05-13 US US12/465,536 patent/US20100112089A1/en not_active Abandoned
- 2009-05-13 CN CN2009801279086A patent/CN102149725A/zh active Pending
- 2009-05-13 RU RU2010150964/04A patent/RU2010150964A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009139497A1 (en) | 2009-11-19 |
| UY31826A (es) | 2010-01-05 |
| US20100112089A1 (en) | 2010-05-06 |
| TW201000116A (en) | 2010-01-01 |
| CN102149725A (zh) | 2011-08-10 |
| RU2010150964A (ru) | 2012-06-20 |
| CL2009001156A1 (es) | 2010-08-27 |
| PE20091924A1 (es) | 2010-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2541217T3 (es) | Diferenciación de células madre mesenquimales | |
| PE20130589A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a | |
| AR071774A1 (es) | Sal de acetato de un compuesto peptidico que tiene actividad antitumoral y su uso. | |
| CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
| AR094178A1 (es) | Derivados de exendina-4 funcionalizada | |
| AR107014A1 (es) | Formulación farmacéutica acuosa | |
| GT200700034A (es) | Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40 | |
| EA201270167A1 (ru) | Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения | |
| ES2531083T3 (es) | Formulaciones estables de polipéptidos y usos de las mismas | |
| MX2009009022A (es) | Vacunas de peptídicas para cánceres que expresan antígenos asociados con tumores. | |
| IL308807B2 (en) | Combination therapy for treating cancer | |
| AR091413A1 (es) | Formulacion de anticuerpos | |
| NZ598610A (en) | High concentration antibody formulations | |
| PE20170140A1 (es) | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer | |
| SG10201804552WA (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
| CO6630082A2 (es) | Tratamiento de lupus nefritis usando laquinimod | |
| AR082805A1 (es) | PEPTIDO O COMPLEJO PEPTIDICO QUE SE UNE A INTEGRINA a2 Y METODOS Y USOS QUE IMPLICAN A LOS MISMOS | |
| MX382443B (es) | Una formulación estable para usarse en el tratamiento de la enfermedad por leucodistrofia metacromática (mld). | |
| PE20121528A1 (es) | Metodos para administrar agentes hipoglucemiantes de larga duracion | |
| PH12012500895A1 (en) | Method for treating heart failure with stresscopin-like peptides | |
| UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa | |
| AR114325A1 (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
| MX2014002062A (es) | Nanoparticulas de peptido y usos de las mismas. | |
| NZ594067A (en) | VISFATIN THERAPEUTIC AGENTS (PEPTIDES, siRNA, FK-866, APO866 ) FOR THE TREATMENT OF ACNE AND OTHER CONDITIONS | |
| EP3501532A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |